An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
← catalyst calendarSponsored by Viridian Therapeutics, Inc. (industry) · VRDN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
132actual
Sites
48
Countries
Germany, Hungary, Netherlands +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-27 | actual | When the study began enrolling |
| Primary completion | 2026-02-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-11-15 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Thyroid Eye Disease
Interventions
- Drug: VRDN-003
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFProptosis Responder Rate in the most proptotic eye as measured by exophtalmometer
measured At Week 24
Permalink · VRDN's whole pipeline · Catalyst calendar · Every registered study · What changed